Showing 2591-2600 of 6036 results for "".
- Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Phase 3 DR Resultshttps://modernod.com/news/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-phase-3-diabetic-retinopathy-results/2481948/Three months after deciding to discontinue tarcocimab tedromer due to two failed late-stage trials, Kodiak Sciences announced it is rebooting its clinical program after its phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to sev
- GALE Extension Study Shows Syfovre Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with GAhttps://modernod.com/news/gale-extension-study-shows-syfovre-continued-to-demonstrate-increasing-treatment-effects-over-3-years-in-patients-with-ga/2481943/Apellis Pharmaceuticals announced data from the GALE extension study following 3 years of continuous treatment with Syfovre (pegcetacoplan injection), the first FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were rep
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes
- FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platformhttps://modernod.com/news/fda-grants-breakthrough-device-status-to-tokus-patented-cardiovascular-risk-ai-clair-platform/2481934/Toku announced that the FDA has granted Breakthrough Device designation to its patented CLAiR technology. According to Toku, the CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive
- AbbVie Enters into Option Agreement with Aldeyra Therapeutics for License to Develop and Commercialize Reproxalaphttps://modernod.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/Aldeyra Therapeutics announced that it has entered into an exclusive option agreement with AbbVie in which AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the US, and an exclusive license to develop, manufacture, and comme
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- Roche Stops Clinical Development of Oral Drug Candidate for Diabetic Retinopathyhttps://modernod.com/news/roche-stops-clinical-development-of-oral-drug-candidate-for-diabetic-retinopathy/2481902/Roche has decided to stop development of vicasinabin, an oral drug cadidate being evaluated for non-proliferative diabetic retinopathy, after completing phase 2 trials, according to a FiercePharma
- Lighthouse Guild to Host Lectures on Ophthalmic Drug Approvals, Technological Innovations, and Advocacy for People with Vision Impairmenthttps://modernod.com/news/lighthouse-guild-to-host-lectures-on-ophthalmic-drug-approvals-technological-innovations-and-advocacy-for-people-with-vision-impairment/2481898/Lighthouse Guild will host three lectures on the latest advances in treatment, technology, and advocacy for people who are blind or have vision loss on Thursday, October 19, 2023, 12-1:30 pm ET, at their headquarters, 250 West 64th Street in Manhattan. Lectures:
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of